000100

YUHAN is a pharmaceutical company founded in 1926 that manufactures and sells prescription drugs, over-the-counter medicines, animal health products, and consumer goods. Its business segments include pharmaceuticals, healthcare, and overseas operations. Key products include the non-small cell lung cancer drug Leqrazza (lazertinib), Antipyrine, Picom C, Duowell, and Kopu Syrup. The company develops active pharmaceutical ingredients (APIs) for HIV and HCV treatments, supplying global partners such as Gilead Sciences. YUHAN also holds license-out agreements with partners like Janssen Biotech and Berlinger Ingelheim for oncology and metabolic disease candidates. The company operates subsidiaries including Yuhan Medica, Wise Med, Yuhan Health Life, and Ad Pharma. It serves domestic and international markets, with a focus on expanding its global presence through API exports and finished drug distribution.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage yuhan.co.kr
Sector Healthcare IR page —
Tags
oncology, active pharmaceutical ingredients, animal health, consumer goods, respiratory diseases, metabolic diseases, license-out, innovative drugs, generic drugs, Leqrazza, lazertinib, Antipyrine, Picom C, Duowell, Kopu Syrup, Elena, Rosuvamiv, Atovamiv, Yuhan Medica, Wise Med, Yuhan Health Life, Ad Pharma, Yuhan Chemical, Yuhan Kimberly, Yuhan SmithKline, Yuhan SP, Yuhan Cyanamide, Yuhan Corax, YH14618, YH25448, YH25724, YH12852, YH42946, YH35995, Lesigercept, Nesfrotamig, YH32364, AD-209, AD-214, AD-216, AD-217, AD-218, AD-223, AD-224, AD-2303, AD-2304, AD-114, NTCB-01/02, YHP2401, AD-211, AD-230, AD-116, AD-232, AD-113, AD-109, AD-115, AD-229
Press page —

Metrics

Valuation  
Market cap ₩ 5.876T
Market cap (USD) $ 4.325B
P/E 22.89
PEG 0.85
P/BV 2.46
P/S 2.57
P/OCF 35.47
P/FCF 218.03
Dividend yield —
Turnover / mcap —
Returns  
ROE 8.6%
ROI 8.2%
ROIC 3.7%
Profit margin 8.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 26.8%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 35.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 2.187T 2.068T 1.859T 1.776T 1.688T 1.62T 1.48T 1.519T 1.462T 1.321T 1.129T 1.017T 943.609B
Net profit 194.079B 70.687B 136.089B 95.144B 102.583B 190.402B 36.612B 58.335B 109.637B 161.249B 126.047B 90.948B 86.461B
Free cash flow 6.626B -62.477B -17.352B 41.234B 52.849B -22.623B 23.222B 47.45B 69.353B -5.932B 44.973B 58.547B 24.017B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 116.3K 109.6K — — — — — — — — — — —
Price performance 12m 0.06 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 236B 284B 343B 397B 443B 461B 497B 559B 609B 694B
↳ YoY growth +10.0% +20.4% +21.0% +15.7% +11.5% +4.2% +7.7% +12.5% +9.0% +14.0%
↳ 5y CAGR +15.6% +14.4% +11.9% +10.2% +8.9% +9.4%
Other receivables (KRW) — — — — — 12.8B 12.4B 15B 17B 19.5B
Borrowings, current (KRW) 51.1B 3.19B 1.3B 15B 48.5B 20.5B 64.1B 4.15B 0.00 —
Borrowings, non-current (KRW) 140B 115B 70.2B 44.3B 46.8B 28.1B 625M 60.2B 105B 71.1B
Bonds payable (KRW) — — — — — — 364M 0.00 0.00 —
Cash and deposits (KRW) 245B 257B 241B 274B 353B 254B 293B 299B 306B 349B
Intangible assets (KRW) 15.9B — — — — 87.6B 138B 298B 285B 300B
Net debt (borrowings + leases - cash) (KRW) -105B -138B -170B -215B -258B -205B -228B -235B -201B -277B
Cash flow detail
Operating cash flow (KRW) 74.1B 126B 93.5B 66B 28.8B 99B 99.5B 144B 54.6B 106B
Purchases of property, plant and equipment (KRW) -80.1B -56.8B -46B -42.8B -51.5B -46.2B -58.3B -161B -117B -99.6B
Purchases of intangible assets (KRW) -4.55B -3.14B -2.59B -3.97B -39.7B -35.7B -36.1B -42.6B -16.8B -34.9B
Change in receivables (cash effect) (KRW) -21.4B -55.6B -59.5B -55.4B -61.2B 8.61B -1.37B 3.42B -1.98B 422M
Change in inventories (cash effect) (KRW) -68.3B 40.7B 23.4B 56.5B -69.3B -26.1B -382M -5.4B -58.6B -33.5B
Change in payables (cash effect) (KRW) -10.2B -45.7B -7.7B 21.3B 11.8B 20.6B -7.81B 44.5B -4.36B -310M
Dividends paid (cash effect) (KRW) -20.5B -20.5B -21.7B -22.7B -23.8B -24.9B -26.1B -27.3B -32.1B -37.5B
Share buybacks (cash effect) (KRW) -1.16B -1.06B -12.3B -8.4B -3.12B -16.4B -16.5B -7.46B -2.51B -20B
Interest paid (cash effect) (KRW) -5.37B -5.44B -5.95B -3.1B -2.48B -2.71B -3.11B -4.3B -12.1B -11.7B
Income taxes paid (cash effect) (KRW) -35B -37.6B -37.7B -35.6B -28B -39.2B -66.2B -32.9B -27.3B -26.5B
Share-based compensation (KRW) — — — — — 689M 464M 339M 1.31B 788M
Operating cash flow before change in receivables (KRW) 95.5B 182B 153B 121B 90B 90.4B 101B 141B 56.6B 106B
Free cash flow (OCF - PPE - intangibles) (KRW) -10.5B 66.2B 44.9B 19.3B -62.3B 17.1B 5.15B -59.9B -79.3B -28.2B
Income detail
Total comprehensive income (KRW) 154B 106B 79.5B 32.8B 213B 124B 91.7B 118B 53.8B 234B
Comprehensive income to owners (KRW) — — — — — 127B 96.5B 120B 69.8B 243B
Provision for credit losses (KRW) — -2.9B 811M 351M 1.19B -1.42B 2.08B 1.33B -145M 2.58B
Credit cost ratio (credit losses / average receivables) (%) — 1.1% 0.3% 0.1% 0.3% 0.3% 0.4% 0.2% 0.0% 0.4%
Reported Apr 2, 2018 Apr 2, 2018 Apr 1, 2019 Mar 30, 2020 Mar 11, 2021 Mar 7, 2024 Mar 12, 2025 Mar 12, 2025 Mar 12, 2025 Mar 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

주식등의대량보유상황보고서(약식) Bull 0 Bear 0 Routine
기업설명회(IR)개최(안내공시) Bull 0 Bear 0 Routine
영업(잠정)실적(공정공시) Bull 0 Bear 5 Results

Prompts

YUHAN (ticker 000100), listed in South Korea.

ETFs Holding YUHAN

ETF Weight in ETF Shares Market value As of
DGRE 0.49% 16,032 $ 726.423K Jun 30, 2026
AVEE 0.34% 7,382 $ 443.209K Nov 16, 2026
DFEV 0.08% 28,492 $ 1.709M Nov 12, 2026
DFSE 0.04% 3,955 $ 237.22K Nov 12, 2026
NTSE 0.02% 248 $ 11.237K Jun 30, 2026
DFEM 0.02% 28,414 $ 1.704M Nov 12, 2026
DFAE 0.02% 26,740 $ 1.604M Nov 12, 2026
DFAX 0.01% 25,389 $ 1.523M Nov 12, 2026
DEXC 0.01% 507 $ 30.41K Nov 12, 2026
AVEM 0.01% 36,271 $ 2.178M Nov 16, 2026
AVSE 0.01% 428 $ 25.697K Nov 16, 2026
AVXC 0.01% 437 $ 26.237K Nov 16, 2026